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The lack of an empirical methodology to
enable normalization among chromatin
immunoprecipitation coupled with mas-
sively parallel DNA sequencing (ChIP-
seq) experiments has limited the precision
and comparative utility of this technique.
Orlando et al. describe a method, called
ChIP with reference exogenous genome
(ChIP-Rx), that allows one to perform
genome-wide quantitative comparisons
of histone modification status across cell
populations using defined quantities of a
reference epigenome. They use the
method to detect disease-relevant epige-
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Epigenomic profiling by chromatin immunoprecipita-
tion coupled with massively parallel DNA sequencing
(ChIP-seq) is a prevailing methodology used to
investigate chromatin-based regulation in biological
systems such as human disease, but the lack of
an empirical methodology to enable normalization
among experiments has limited the precision and
usefulness of this technique. Here, we describe a
method called ChIP with reference exogenous
genome (ChIP-Rx) that allows one to perform
genome-wide quantitative comparisons of histone
modification status across cell populations using
defined quantities of a reference epigenome. ChIP-
Rx enables the discovery and quantification of dy-
namic epigenomic profiles across mammalian cells
that would otherwise remain hidden using traditional
normalization methods. We demonstrate the utility
of this method for measuring epigenomic changes
following chemical perturbations and show how
reference normalization of ChIP-seq experiments en-
ables the discovery of disease-relevant changes in
histone modification occupancy.INTRODUCTION
The ability to map genomic occupancy of transcriptional regula-
tors, histone posttranslational modifications, and DNA methyl-
ation (epigenomic modifications) has enabled the elucidation of
transcriptional mechanisms, genome organization, mapping of
functional regulatory elements, and discovery of disease-associ-
ated chromatin markers (Badeaux and Shi, 2013; Barski et al.,
2007; Lee and Young, 2013; Rivera and Ren, 2013; Zhou et al.,
2011). Such targeted and large-scale epigenome mapping
efforts have revealed chromatin regulatory proteins that are ther-
apeutic targets for a wide variety of human diseases (Azad et al.,
2013; Dawson and Kouzarides, 2012; Deshpande et al., 2012;
Wee et al., 2014). Many of these chromatin regulators exhibit
cell-type-selective, gene-selective, or disease-relevant effects,Cell Rcreating a critical need to study the chromatin modifications
catalyzed by these regulators. Accurate quantification of both
global and loci-specific chromatin modifications is needed to
allow the discovery and characterization of epigenomic regula-
tors and epigenome-modulating agents.
Traditional ChIP-seq methodologies are not inherently quanti-
tative and therefore do not allow direct comparisons between
samples derived from different cell types or between cells
that have experienced a perturbation, such as a genomic alter-
ation or chemical treatment. For example, if we employ the tradi-
tional reads per million (RPM) ChIP-seq normalization method, a
cell population containing chromatin state ‘‘A’’ (a high level of
histone posttranslational modification) will appear similar to a
cell population containing chromatin state ‘‘B,’’ where 50% of
the signal has been removed (Figure 1A), because the signal
is quantified as a simple percentage of all mapped reads. More-
over, additional variables, such as variations in genome frag-
mentation, immunoprecipitation efficiency, or other experi-
mental steps, frequently confound analysis. Efforts to correct
for these variables have produced in silico normalization strate-
gies, but an empirical method to enable direct and quantitative
comparisons among epigenomic ChIP-seq data sets is still
lacking (Bardet et al., 2012; Landt et al., 2012; Liang and Kelesx,
2012; Liu et al., 2013; Nair et al., 2012). Because of the
experimental and analytical restrictions of ChIP-seq, a robust
normalization methodology is needed to quantify epigenome
differences among varying cell populations, treatments, and
genomic states.RESULTS
Here we present a method, called ChIP with reference exoge-
nous genome (ChIP-Rx), that utilizes a constant amount of refer-
ence or ‘‘spike-in’’ epigenome, added on a per-cell basis, to
allow direct comparison between two ormoreChIP-seq samples
(Figure 1B). Analogous methodologies have been applied in
areas of gene-expression analysis that have revealed global
transcriptional amplification upon normalization and in Meth-
ylC-seq, where bisulfate conversion rates have been normalized
(Kanno et al., 2006; Krueger et al., 2012; Lin et al., 2012; Love´n
et al., 2012; van de Peppel et al., 2003). These advancements
have allowed standardization, precision, and a mechanisticeports 9, 1163–1170, November 6, 2014 ª2014 The Authors 1163
Figure 1. Normalization and Interpretation of ChIP-Seq Data
(A) Schematic representation of a typical ChIP-seq data workflow. Interrogation of a human epigenome (Blue circles, nucleosomes) with a full complement of
histone modification (red circles, top) versus an epigenome with a half complement of histone modification (red circles, bottom). ChIP, sequencing, and mapping
using reads per million (RPM) reveals ChIP-seq peaks (blue). A comparison of the peaks as a percentage of the total reads reveals little difference.
(B) Schematic representation of a ChIP-seq data workflowwith reference genome normalization. Interrogation of a human epigenome (Blue circles, nucleosomes)
with a full complement of histone modification (red circles, top) versus an epigenome with a half complement of histonemodification (red circles, bottom). A fixed
amount of reference epigenome (orange, nucleosomes; red, histone modifications) is added to human cells in each condition. After ChIP, sequencing, and
mapping, the ChIP sequence reads are normalized to the percentage of reference genome reads in the sample (reference-adjusted RPM [RRPM]). A comparison
of ChIP-seq signals using normalized reads reveals a 50% difference between peaks. This method is called ChIP with reference exogenous genome (ChIP-Rx).understanding of RNA transcription (van Bakel and Holstege,
2004; Jiang et al., 2011; Li et al., 2013); however, no cell-
count-normalized methods have been applied to global correc-
tion of histone posttranslational modifications. Since a vast array
of histone modifications have been described in eukaryotic
cells that play roles in organismal development, maintenance
of cell state, differentiation, and disease, including those associ-
ated with transcriptional processes, genome organization,
DNA repair, and cell-cycle progression (Calo and Wysocka,
2013; Pastor et al., 2013; Rinn and Chang, 2012; Rivera and
Ren, 2013; Tan et al., 2011; Tian et al., 2012), a quantitative
method for comparing these key marks is needed. We reasoned
that the Drosophila melanogaster genome would be a desir-
able exogenous reference for mammalian cells because the
Drosophila genome is well studied and has a high-quality
sequence assembly, there is minimal mapping of the Drosophila
genome sequence to human or mouse genomes (>0.05%; Table
S1; Supplemental Experimental Procedures), Drosophila cells
are readily available in large quantities, and theDrosophila epige-
nome displays nearly all of the key histone modification marks
reported in humans. Moreover, histone proteins are among the
most conserved proteins from humans to yeast, indicating that1164 Cell Reports 9, 1163–1170, November 6, 2014 ª2014 The Authavailable ChIP-quality antibodies would likely recognize both
Drosophila and human chromatin (Sullivan et al., 2002; Wolffe
and Pruss, 1996).
To determine the impact of mixing interspecies epige-
nomes, we tested whether the addition of a reference genome
(Drosophila S2 cells) would inherently affect our ability to detect
a histone modification within the test sample (human cells) using
ChIP-seq. We compared Jurkat cells alone with Jurkat cells that
had been mixed with Drosophila cells and analyzed the resulting
histone H3 lysine-79 dimethyl (H3K79me2) ChIP-seq profiles
(Figure S1; Table S2). We determined that mixing of Drosophila
and human cells did not induce large-scale changes in the
H3K79me2 profiles, as the profiles of these cell populations
were highly correlated by total signal as well as enriched
loci overlap (Pearson correlation = 0.96; Supplemental Experi-
mental Procedures). Moreover, reads originating from human
or Drosophila could be separated with 99% accuracy (Supple-
mental Experimental Procedures). Together, these results indi-
cate that the addition of a reference genome did not impede
our ability to detect histone mark occupancy.
We devised an experiment to test our ability to detect changes
in histone modification occupancy throughout the humanors
Figure 2. Experimental Design of Differen-
tial H3K79me2 Detection
(A) Schematic representation of differential
H3K79me2 detection and normalization strate-
gies. Two populations of cells were produced: a
human epigenome (blue nucleosomes) with a full
complement of H3K79me2 (red circles, top left)
and a human epigenome (blue nucleosomes)
with depleted H3K79me2 due to EPZ5676 expo-
sure (top right). These cells were mixed in defined
proportions in order to allow a dilution of total
genomic histone modification (dark red to pink).
Cell mixtures were subjected to ChIP-seq in the
presence of the reference Drosophila epigenome
(orange). ChIP-seq signals were calculated based
on traditional or Drosophila-reference-normalized
methods. See also Figure S1.
(B)Western blot validation of H3K79me2 depletion
in Jurkat cells. Mixtures of 0%–100% EPZ5676-
treated cells (0:100; 25:75; 50:50, 75:25; 100:0 proportions of [DMSO-treated:EPZ5676-treated] cells) were measured by immunoblot (IB) for the presence of
H3K79me2, H3K4me3, or total histone H3 (loading control). Treated cells were exposed to 20 mM EPZ5676 for 4 days.
See also Table S1.epigenome using ChIP-Rx (Figure 2A). We reasoned that an
initial test of ChIP-Rx normalization should feature an epige-
nomic modification that could be readily removed and was not
essential for cell viability in themodel cell line. Using the selective
DOT1L inhibitor EPZ5676 (Daigle et al., 2013), we depleted the
Histone H3 lysine-79 dimethyl (H3K79me2) modification from
Jurkat cell bulk histones (Figure 2B). The H3K79me2 modifica-
tion is catalyzed by the DOT1L protein and is associated with
the release of paused RNA Polymerase II and licensing of tran-
scriptional elongation (van Leeuwen et al., 2002; Ng et al.,
2002; Shanower et al., 2005; Steger et al., 2008). This modifica-
tion is typically deposited within the 50 regions of genes and its
presence is not critical for Jurkat cell viability (Daigle et al.,
2011, 2013; Schu¨beler et al., 2004; Steger et al., 2008). Bymixing
untreated cells (full H3K79me2) with EPZ5676-treated cells
(H3K79me2 depleted), we created a set of cell populations
with defined quantities of H3K79me2, as verified by immunode-
tection (Figure 2B). To each of these cell populations we added
Drosophila cells at a ratio of one Drosophila cell per two hu-
man cells, which provided a constant ‘‘reference’’ amount of
H3K79me2 per human cell. We performed ChIP-seq from sam-
ples consisting of 0:100, 25:75, 50:50, 75:25, and 100:0 propor-
tions of EPZ5676 to DMSO-treated Jurkat cells. We then tested
whether traditional ChIP-seq analysis methods would reveal the
decrease in human per-cell H3K79me2 occupancy and, if not,
whether the addition of the Drosophila epigenome would allow
detection of H3K79me2 removal.
A key prediction of our normalization method is that as the
global level of a histone modification is depleted in human cells,
the percentage of total reads mapping to the reference
Drosophila genome should increase. This is because the con-
stant amount of reference genome added per human cell
accounts for a greater percentage of total ChIP DNA fragments
as human epitopes are lost (see the ratio of blue to orange
DNA fragments in Figure 1B). To test this prediction, we interro-
gated cells with defined H3K79me2 levels (Figure 2B) by ChIP-
Rx to measure genomic H3K79me2 occupancy. As a control,
we also measured H3K4me3 occupancy, which is a histoneCell Rmodification that is not appreciably changed within our test
cell populations (Figure 2B). As predicted, H3K79me2 depletion
in Jurkat cells both reduced ChIP-Rx reads mapping to the hu-
man genome and increased reads mapping to the Drosophila
genome (Figure 3A). We did not observe a similar change in
the mapping ratio for H3K4me3 in the same samples, consistent
with the finding that H3K4me3 was not preferentially removed
from the human genome (Figure 3B). These results demonstrate
that a reference genome can internally normalize the read count.
We next used the reference Drosophila genome to quantita-
tively normalize across experiments. To make ChIP-seq data
quantitative on a per-cell basis, it is necessary to introduce a
reference signal that is constant per cell, fromwhich a normaliza-
tion factor can be derived. Our ChIP-Rx protocol uses the signal
from a fixed amount ofDrosophila genome per human cell as this
reference. We derived a normalization factor (see the Supple-
mental Experimental Procedures) for each experiment, such
that the resulting Drosophila signal was equilibrated across all
experiments (Table S2; Figure S2). Using traditional RPM
normalization, the loci-specific ChIP-seq profiles and metagene
profiles for H3K79me2 and H3K4me3 appear unchanged for the
majority of samples (Figures 3C–3F), despite evidence that the
H3K79me2 modification is progressively depleted (Figure 2B).
After normalization with the Drosophila reference (normalized
reference-adjusted RPM [RRPM]), a striking and gradated
decrease in H3K79me2 signal across the samples is evident
(Figures 3C, 3E, 3G, and S3). Normalization did not appreciably
affect the metagene profiles of the control H3K4me3 experi-
ments (Figures 3D, 3F, 3H, and S3). Repeat experiments pro-
duced the same result in all cases: normalization revealed a
loss of H3K79me2 across the samples and H3K4me3 profiles
were not significantly affected (Figure S4). These results indicate
that normalization to a Drosophila reference is an effective
method for quantitatively comparing multiple experiments and
can reveal changes in histone modification that may not be
apparent without proper normalization.
Having validated the ChIP-Rx methodology using standard-
ized quantities of H3K79me2, we next tested our ability toeports 9, 1163–1170, November 6, 2014 ª2014 The Authors 1165
Figure 3. ChIP-Rx Reveals Quantitative Epigenome Changes
(A and B) Percentage of reads aligning to either test (human, blue) orDrosophila (reference, orange) genomes after H3K79me2 ChIP-Rx (A) or H3K4me3 ChIP-Rx
(B). Samples containing 0%, 25%, 50%, 75%, or 100% EPZ5676 treated Jurkat cells were used as defined in Figure 2B.
(C and D) Sequenced reads from H3K79me2 (C) and H3K4me3 (D) immunoprecipitations at the RPL13A gene locus in traditional reads per million (RPM,top) or
reference-adjusted reads per million (RRPM, bottom; see Experimental Procedures). Color indicates the percentage of sample treated with EPZ5676. The gene
model is shown below the track.
(E) Meta-gene profile of H3K79me2-occupied genes in Jurkat cells. Meta-gene profiles were produced with traditional RPM (left) or RRPM (right). Color indicates
the percentage of Jurkat cell sample treated with EPZ5676 as in Figure 2B. Region 5 to +10 kb around the transcription start site (TSS) is shown. Meta-gene
profile was derived from top 5,000 protein-coding genes as defined by total H3K79me2 signal in the 0% treated (untreated with EPZ5676) sample. A meta-gene
profile representing all genes is shown in Figure S3.
(F) Meta-gene profile of H3K4me3-occupied genes in Jurkat cells. Meta-gene profiles were produced with traditional RPM (left) or RRPM (right). Color indicates
the percentage of Jurkat cell sample treated with EPZ5676 as in Figure 2B. Region 5 to +10 kb around the transcription start site (TSS) is shown. Meta-gene
profile was derived from top 5,000 protein-coding genes as defined by total H3K4me3 signal in the 0% treated (untreated with EPZ5676) sample. A meta-gene
profile representing all genes is shown in Figure S3.
(G and H) Line graphs display the observed fold-change difference in average meta-gene signal across the 5 to +10 kb window around the TSS for each
H3K79me2 (G) or H3K4me3 (H) ChIP sample (x axis) relative to the signal from the 0% treated population using traditional (gray) or reference (black) normalization.
See also Figures S2–S4 and Table S2.normalize between ChIP-seq experiments in a disease-relevant
system. MV4;11 acute myelomonocytic leukemia cells are a
DOT1L-inhibitor sensitive model of human mixed-lineage-linked
leukemia, a disease characterized by reciprocal translocations1166 Cell Reports 9, 1163–1170, November 6, 2014 ª2014 The Authof the mixed-lineage leukemia (MLL) gene (Daigle et al., 2011,
2013; Deshpande et al., 2012). We treated MV4;11 cells with
DOT1L inhibitor and measured changes in H3K79me2 occu-
pancy in the presence or absence of the reference Drosophilaors
Figure 4. ChIP-Rx Reveals Epigenomic Alterations in Disease Cells that Respond to Drug Treatment
(A) Western blot showing the levels of H3K79me2 in MV4;11 cells after treatment for 4 days with increasing concentrations of EPZ5676.
(B) Percentage of H3K79me2 ChIP-seq reads aligning to either test (human, blue) or Drosophila (reference, orange) genomes after H3K79me2 ChIP-Rx from
MV4;11 cells treated as in (A).
(C) Sequenced reads from H3K79me2 immunoprecipitations at the REXO1 gene locus in standard RPM (top) or RRPM (bottom) (see Experimental Procedures).
Color indicates the concentration of EPZ5676 given to each sample. The gene model is shown below the track.
(D) Meta-gene profile of H3K79me2-occupied genes in MV4;11 cells. Meta-gene profiles were produced with traditional Reads Per Million (RPM, left) or
Reference-adjusted Reads Per Million (RRPM, right). Color indicates the concentration of EPZ5676 used in each sample. The region 5 kb to +10 kb around the
TSS is shown. Meta-gene profile was derived from top 5,000 protein-coding genes as defined by total H3K79me2 signal in the 0nM treated (untreated with
EPZ5676) sample. A meta-gene profile representing all genes is shown in Figure S3.
(E) Line graph displays the observed fold-change difference in average meta-gene signal across the 5 to +10 kb window around the TSS for each H3K79me2
ChIP sample (x axis) relative to the signal from the 0 nM treated population using standard (gray) or reference (black) normalization.
(F) Box plots display the distribution of the observed fold change of H3K79me2 signal 5 kb to +10 kb around the TSS of all genes between the 0 nM and 5 nM
treated samples (blue, MV4;11; green, Jurkat) for all genes using traditional (left) or reference-adjusted (right) normalization (see the Supplemental Experimental
Procedures).
See also Figures S3 and S5 and Table S2.epigenome (Figures 4A–4E, S5A, and S5B). EPZ5676 induced a
dose-dependent decrease in bulk H3K79me2 (Figure 4A), but
this result was masked when we quantified H3K79me2 occu-
pancy using traditional normalization (Figures 4C and 4E). We
observed a dose-dependent decrease in H3K79me2 genomic
occupancy only after employing reference normalization (Fig-
ures 4C–4E). This unmasking of epigenomic effects may be crit-
ical for understanding the cell-type-selective effects of small-
molecule epigenome modulators. For example, MV4;11 cells
exhibit global H3K79me2 depletion at a low dose of EPZ5676,
consistent with the known selectivity of the DOT1L inhibitor for
leukemic cells carrying MLL translocations, but EPZ5676-insen-
sitive Jurkat cells do not (Figures 4A andS5C; Daigle et al., 2013).Cell RThus, normalizing to a reference exogenous genome rectifies the
protein-level measurements and genome occupancy of modi-
fied histones, and reveals subtle epigenomic changes that may
underlie or predict cellular responses to drugs (Figure 4). These
results show that ChIP-Rx enables the discovery of epigenomic
changes that can provide insight into disease and inform drug
mechanisms.
DISCUSSION
In summary, we have demonstrated that ChIP-Rx allows the dis-
covery and quantification of dynamic epigenomic profiles across
mammalian cells that would otherwise remain hidden usingeports 9, 1163–1170, November 6, 2014 ª2014 The Authors 1167
traditional normalization methods. A recent study employed a
similar reference strategy for ChIP-seq normalization (Bonhoure
et al., 2014); however, our method offers two crucial advantages
that allow direct comparative epigenomic analysis. First, our
method introduces the reference at the beginning of the experi-
ment, thus normalizing for variation throughout the experiment,
including chromatin fragmentation and immunoenrichment, both
of which are critical for epitope and genome retrieval (Kidder
et al., 2011; Meyer and Liu, 2014; Raha et al., 2010). Second, as
was analogously shown for RNA expression correction (Love´n
et al., 2012), our method introduces the reference ‘‘spike-in’’ on
a per-cell basis as opposed to total chromatin, thus allowing
the detection of unidirectional chromatin changes irrespective of
variations in ploidy or gross chromatin. Thus, ourmethodprovides
greater accuracy in determining epigenome changes that occur
upon cell perturbation or exposure to small-molecule inhibitors
as compared with current methods. Importantly, ChIP-Rx allows
for the detection of subtle epigenomic changes, as opposed to
qualitative occupancy calls, and thus advances the ChIP-seq
methodology fromadescriptive,binary readout toone that reveals
gradated epigenomic changes. This is particularly important for
thedose-rangingcharacterizationofchemical tools and therapeu-
tics targeting chromatin-associated complexes via genome-wide
approaches. Application of this methodology to additional model
systems, including mouse, rat, and zebrafish (Table S1), as well
as additional histone modifications, including repressive (i.e.,
H3K27me3) and activating (i.e., H3K27ac) histone modifications,
will enable far-reaching studies of comparative epigenomics.
We recommend the implementation of ChIP-Rx whenever
quantitative or comparative epigenomic changes are under
investigation. The method described here will be critical for un-
derstanding the global and site-selective epigenomic changes
that occur in human disease, during cell-state changes, and
especially the action of small-molecule inhibitors of chromatin-
modulating proteins.
EXPERIMENTAL PROCEDURES
Human Cell Lines, Growth, and Treatment
Jurkat cells were obtained from ATCC and maintained in RPMI (Life
Technologies) supplemented with 10% fetal bovine serum (FBS; Life Technolo-
gies) at 5%CO2 in37
C.MV4;11cellswereobtained fromATCCandmaintained
in RPMI (Life Technologies) supplemented with 10% FBS at 5% CO2 in 37
C.
Jurkat cells were treated with DMSO or EPZ5676 (Selleck Chemicals, cata-
log number S7062) at 5 nM or 20 mM for 4 days, and MV4;11 cells were treated
with DMSO or EPZ5676 at 0.5 nM, 2 nM, or 5 nM for 4 days. Live-cell numbers
were quantified using the Countess cell counter (Life Technologies).
At harvest, cells were crosslinked with 1% formaldehyde by addition of 1/10
volume of fresh 11% formaldehyde solution (11% formaldehyde 0.1 M NaCl,
1 mM EDTA, 0.5 mM EGTA, 50 mM HEPES) and incubation at room tempera-
ture for 8 min. Crosslinking reactions were quenched with a 1/20 volume of
2.5 M glycine for 1–5 min and cells were pelleted. The cells were then washed
three times with ice-cold PBS. Washed cell pellets were flash frozen and
stored at 80C.
Preparation of Drosophila S2 Cells
Drosophila S2 cells (ATCC catalog number CRL-1963; Biovest part number
OO.763/OO.627) were cultured in Schneider’sDrosophilamedia (Life Technol-
ogies catalog number 21720-024) supplemented with 10% FBS to attain a
density of 0.5–0.6 3 106 cells/ml. Cell culture and scale-up to 2 L was per-
formed by Biovest International.1168 Cell Reports 9, 1163–1170, November 6, 2014 ª2014 The AuthAt harvest, cells were crosslinked with 1% formaldehyde by addition of a
1/10 volume of fresh 11% formaldehyde solution (11% formaldehyde 0.1 M
NaCl, 1mMEDTA, 0.5 mMEGTA, 50mMHEPES) and incubation at room tem-
perature for 8 min. Crosslinking reactions were quenched with a 1/20 volume
of 2.5 M glycine for 1–5 min and cells were pelleted. The cells were then
washed three times with ice-cold PBS. Washed cell pellets were flash frozen
and stored at 80C at 1 3 108 cells per aliquot.
ChIP-Rx
For each ChIP-Rx experiment, a 2:1 ratio of human:Drosophila cells was used.
This corresponds to 20 million crosslinked human cells and 10 million cross-
linked S2 cells (Jurkat experiments) or 15 million crosslinked human cells
and 7.5 million crosslinked S2 cells (MV4;11 experiments).
S2 cells were added to human cells at the beginning of the ChIP-Rx work-
flow (during nuclei isolation). Once Drosophila S2 and human cells were com-
bined, the sample was treated as a single ChIP-seq sample throughout the
experiment until completion of DNA sequencing.
Briefly, frozen, crosslinked human andDrosophila cells were resuspended in
parallel in cold Lysis Buffer 1 (140 mMNaCl, 1 mM EDTA, 50 mMHEPES, 10%
glycerol, 0.5% NP-40, 0.25% Triton-X-100), incubated 10 min at 4C, and pel-
leted. Both human andDrosophila cell sampleswere resuspended in parallel in
Lysis Buffer 2 (10 mM TRIS [pH 8.0], 200 mM NaCl, 1 mM EDTA, 0.5 mM
EGTA), incubated for 10 min at 4C, and combined to the desired cell number
ratios (two human cells per one Drosophila cell). The composite cell nuclei was
then pelleted and resuspended in sonication buffer (10 mM TRIS [pH 8.0],
1 mM EDTA, 0.1% SDS).
Composite samples (human + Drosophila S2) in sonication buffer were son-
icated using a Covaris E220 sonication water bath for 5 min. Sheared chro-
matin was diluted 1:1 in 23 dilution buffer (300 mM NaCl, 2 mM EDTA,
50 mM TRIS [pH 8.0], 1.5% Triton-X, 0.1% SDS) and incubated with either
H3K79me2 (Abcam 3594)- or H3K4me3 (Millipore 07-473)-conjugated Protein
G Dynal beads (Invitrogen) overnight (8–16 hr, rotating) at 4C, and then
washed two times with wash buffer 1 (50 mM HEPES, 140 mM NaCl, 1 mM
EDTA, 1 mM EGTA, 0.75% Triton-X, 0.1% SDS, 0.05% DOC), two times
with high-salt wash buffer (50 mM HEPES, 500 mM NaCl, 1 mM EDTA,
1 mM EGTA, 0.75% Triton-X, 0.1% SDS, 0.05% DOC), and one time with
TE-NaCl buffer (10 mM Tris [pH 8.0], 1 mM EDTA, 50 mM NaCl). Samples
were eluted from beads for 1 hr at 65C in elution buffer (50 mM TRIS [pH
8.0], 10 mM EDTA, 1% SDS) and supernatant reverse-crosslinked at 65C
for 6–16 hr. Samples were diluted 1:1 with TE buffer (50 mM TRIS [pH 8.0],
1 mM EDTA) and treated with RNase A (0.2 mg/ml) for 2 hr at 37C and then
Proteinase K (0.2 mg/ml) for 2 hr at 55C. DNA was isolated by phenol-chloro-
form extraction and ethanol precipitation. For detailed protocols see the Sup-
plemental Experimental Procedures and Guenther et al. (2008).
Library Construction, Sequencing, and Data Collection
Libraries were constructed with the Illumina Tru-Seq library preparation kit
using a target fragment size of 200–400 bp and multiplexing barcodes.
Libraries were sequenced using Illumina HiSeq 2000 with single-end reads
for 40 cycles. Sequences were demultiplexed and aligned using Bowtie2
against a ‘‘genome’’ that combines the human hg19 genome and the
Drosophila dm3 genome (see the Supplemental Experimental Procedures). In-
dividual accession numbers and read statistics available in Table S2.
Western Blots
Cells were harvested from all treatment groups and lysed with Triton extraction
buffer (PBS containing 0.5% Triton X-100 [v/v], cOmplete Protease Inhibitors
[Roche]) for 10 min with rotation. Nuclei were collected and acid extracted
with 0.2 NHCl overnight. Histone proteins were collected from the supernatant
and immunoblotted for H3K4me3 (Millipore 07-473), H3K79me2 (Abcam
3594), and histone H3 (Abcam 1791).
Determination of the Normalization Factor
A complete description of the basis and derivation of the ChIP-Rx normaliza-
tion factor is provided in the Supplemental Experimental Procedures. In brief,
we derived a normalization constant, a, such that after normalization the signalors
per-reference cell (b) is the same across all samples. The total ChIP-seq signal
derived from reference cells is simply the count of reads (in millions) aligning to
theDrosophila genome, which we represent as Nd. Because the percentage of
reference cells as a fraction of the total number of cells is constant and we
assume that the epigenome of the reference cells does not vary appreciably,
we can derive a as
a  Nd = b
Because b is a constant, we can simply rewrite this as






multiplying the read counts by a produces a normalized read count in normal-
ized RRPM.
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